Cart
sales@molnova.com
TG-89
CAS No. 936091-56-4
TG-89( —— )
Catalog No. M33687 CAS No. 936091-56-4
TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 85 | Get Quote |
|
| 5MG | 149 | Get Quote |
|
| 10MG | 237 | Get Quote |
|
| 25MG | 382 | Get Quote |
|
| 50MG | 544 | Get Quote |
|
| 100MG | 718 | Get Quote |
|
| 500MG | 1431 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameTG-89
-
NoteResearch use only, not for human use.
-
Brief DescriptionTG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and cervical cancer.
-
DescriptionJAK-IN-32 (XC) is a bi-aryl meta-pyrimidine inhibitor of JAK kinase.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetFLT
-
RecptorFLT | JAK | c-RET
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number936091-56-4
-
Formula Weight510.65
-
Molecular FormulaC26H34N6O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCc1cnc(Nc2cccc(CN3CCOCC3)c2)nc1Nc1cccc(c1)S(=O)(=O)NC(C)(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Glenn Noronha, et al. Bi-aryl meta-pyrimidine inhibitors of kinases. Patent. US20110212077A1.
molnova catalog
related products
-
MRX-2843
MRX-2843 is a potent and orally active inhibitor of MERTK and FLT3(IC50s of 1.3 nM and 0.64 nM, respectively).
-
JI6
JI6 (JAK3 Inhibitor VI) is a potent, selective and orally active FLT3 inhibitor. JI6 exhibits IC50s of ～40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively.
-
7BIO
7-bromoindirubin-3'-oxime (7BIO) is a caspase independent nonapoptotic cell death inducer. 7BIO is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kinases.
